Dublin, May 29, 2019 (GLOBE NEWSWIRE) -- The "Diabetes Care Intelligence Center 2012-2023" report has been added to ResearchAndMarkets.com's offering.
The Diabetes Care Intelligence Center (IC) is a global intelligence database on diabetes drugs & devices, which offers data on 25 major countries. It covers 13 years of comparable data, including 5-year forecasts incorporating value, volume sales, and price and price per-capita expenditure. The Intelligence Centre enhances your understanding of the diabetes drugs industry, along with economic factors impacting diabetes drug usage, such as diabetes population, Type 1 and Type 2 Diabetic population, and obesity, which provide you with actionable business insights.
Market Scope
The Diabetes Care Intelligence Center provides exhaustive coverage (countries covered account for more than 80% of the overall spending on diabetes). Covering and tracking of over 18,000 data points of the diabetes drugs industry, which covers various categories, segments, Active Pharmaceutical Ingredients (APIs), and brands. It also covers more than 8,000 data points of the diabetes care device market, which encompass various categories, segments, sub-segments and company share analysis.
Market Overview
The global diabetes care market is expected to grow because of the growing diabetes population levels and increasing diabetes expenditure in established, as well as pharm emerging countries.
Global Rise in Diabetic Population
The United States Leads the Diabetes Drugs & Devices Market
Reasons to Purchase this Dashboard
Customization of the Dashboard
This dashboard can be customized to meet your requirements by adding the country of your choice and qualitative trends on request. Please connect with our Customer Service team, who will assist to get a dashboard that suits your needs.
Key Topics Covered:
1. Introduction
1.1 Key Deliverables of the Study
1.2 Market Definition
2. Research Approach and Methodology
2.1 Introduction
2.2 Research Designs
2.3 Study Phases
2.3.1 Internal Sources Evaluation
2.3.2 Research Process
2.3.3 Modeling & Triangulation
2.3.4 Data Finalization
2.3.5 Expert Validation
3. Market Segmentation
3.1 By Drug
3.1.1 Oral Anti-diabetic drugs
3.1.1.1 Biguanide
3.1.1.1.1 Metformin
3.1.1.2 Alpha - Glucosidase Inhibitors
3.1.1.2.1 Alpha - Glucosidase Inhibitors
3.1.1.3 Dopamine -D2 Receptor Agonist
3.1.1.3.1 Bromocriptin (Cycloset)
3.1.1.4 Sodium - Glucose Cotransport - 2 (SGLT-2) Inhibitor
3.1.1.4.1 Invokana (Canagliflozin)
3.1.1.4.2 Jardiance (Empagliflozin)
3.1.1.4.3 Farxiga/Forxiga (Dapagliflozin)
3.1.1.4.4 Suglat (Ipragliflozin)
3.1.1.5 Dipeptidyl peptidase - 4 (DPP-4) inhibitors
3.1.1.5.1 Januvia (Sitagliptin)
3.1.1.5.2 Onglyza (Saxagliptin)
3.1.1.5.3 Tradjenta (Linagliptin)
3.1.1.5.4 Vipidia/Nesina (Alogliptin)
3.1.1.5.5 Galvus (Vildagliptin)
3.1.1.6 Sulfonylureas
3.1.1.6.1 Sulfonylureas
3.1.1.7 Meglitinide
3.1.1.7.1 Meglitinide
3.1.2 Insulin
3.1.2.1 Basal or Long-acting Insulins
3.1.2.1.1 Lantus (Insulin Glargine)
3.1.2.1.2 Levemir (Insulin Detemir)
3.1.2.1.3 Toujeo (Insulin Glargine)
3.1.2.1.4 Tresiba (Insulin Degludec)
3.1.2.1.5 Basaglar (Insulin Glargine)
3.1.2.2 Bolus or Fast Acting Insulins
3.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)
3.1.2.2.2 Humalog (Insulin Lispro)
3.1.2.2.3 Apidra (Insulin Glulisine)
3.1.2.3 Traditional Human Insulins
3.1.2.3.1 Novolin/Actrapid/Insulatard
3.1.2.3.2 Humilin
3.1.2.3.3 Insuman
3.1.2.4 Biosimilar Insulins
3.1.2.4.1 Insulin Glargine Biosimilars
3.1.2.4.2 Human Insulin Biosimilars
3.1.3 Non-Insulin Injectable Drugs
3.1.3.1 GLP1 Receptor Agonists
3.1.3.1.1 Victoza (Liraglutide)
3.1.3.1.2 Byetta (Exenatide)
3.1.3.1.3 Bydureon (Exenatide)
3.1.3.1.4 Trulicity (Dulaglutide)
3.1.3.1.5 Lyxumia (Lixisenatide)
3.1.3.2 Amylin Analogue
3.1.3.2.1 Symlin (Pramlintide)
3.1.4 Combination Drugs
3.1.4.1 Insulin Combinations
3.1.4.1.1 NovoMix (Biphasic Insulin Aspart)
3.1.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
3.1.4.1.3 Xultophy (Insulin Degludec and Liraglutide)
3.1.4.2 Oral Combination
3.1.4.2.1 Janumet (Sitagliptin and Metformin HCl)
3.2 By Device
3.2.1 Monitoring Devices
3.2.1.1 Self-monitoring Blood Glucose Devices
3.2.1.1.1 By Component
3.2.1.1.1.1 Glucometer Devices
3.2.1.1.1.2 Test Strips
3.2.1.1.1.3 Lancets
3.2.1.1.2 By End User
3.2.1.1.2.1 Hospital
3.2.1.1.2.1.1 Glucometer Devices
3.2.1.1.2.1.2 Test Strips
3.2.1.1.2.1.3 Lancets
3.2.1.1.2.2 Personal
3.2.1.1.2.2.1 Glucometer Devices
3.2.1.1.2.2.2 Test Strips
3.2.1.1.2.2.3 Lancets
3.2.1.2 Continuous Blood Glucose Monitoring
3.2.1.2.1 By Component
3.2.1.2.1.1 Sensors
3.2.1.2.1.2 Receivers
3.2.2 Management Devices
3.2.2.1 Insulin Pump
3.2.2.1.1 Insulin Pump Device
3.2.2.1.2 Insulin Pump Reservoir
3.2.2.1.3 Infusion Set
3.2.2.2 Insulin Syringes
3.2.2.3 Insulin Cartridges
3.2.2.4 Disposable Pens
3.2.2.5 Jet Injectors
3.3 Geography
4. Market Indicators
4.1 Type-1 Diabetes Population (2012-2023)
4.2 Type-2 Diabetes Population (2012-2023)
5. Company Share Analysis
For more information about this report visit https://www.researchandmarkets.com/r/fewa7q
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Endocrinology